

# 澳大利亚生物技术协会 澳大利亚医疗技术公司名录



## 公司介绍

公司名称: Global Kinetics Corporation

主要联系人姓名: Andrew Maxwell

主要联系人职务: 董事总经理兼首席执行官

公司网址: [www.globalkineticscorp.com](http://www.globalkineticscorp.com)

公司地址: Level 6, 530 Collins Street, Melbourne VIC 3000

公司是未上市

## 公司简介

Global Kinetics Corporation (GKC) 成立于 2007 年, 是一家总部位于澳大利亚墨尔本的医药科技公司, 其主打产品为 Parkinson's KinetiGraph (PKG)。

帕金森病所表现出的主要运动失调症状为运动迟缓和运动障碍, 对于这种病症的存在及严重程度, PKG 能够为临床神经学专科医生提供一份详尽的报告。该报告能够使医学专家判断患者的用药机制是否合理以及是否需要做出调整。PKG 报告中的数据通过一种手表式数据记录仪进行采集, 在数据采集过程中, 患者需在居家环境中佩戴该记录仪 10 天时间。

GKC 公司致力于推动 PKG 的全球商业化运作, 帮助神经学专科医生更好地治疗运动失调, 让患者享受更高质量的生活, 购买者获得更好的健康经济效益。PKG 拥有澳大利亚药品管理局 (TGA) 的许可和 CE 标志, 且其产品已成为亚洲、欧洲、澳大利亚医院中对帕金森病的常规疗法。在 2014 年将获得美国食品药品监督管理局 (FDA) 的批准, 登陆美国市场销售。

## 关键技术或领先技术

PKG 报告为临床医生提供了一份对患者临床状况的客观评估, 这其中包含了对运动迟缓和运动障碍的定量测量, 将病症变化与用药时间相对应。该报告在不同期间皆具有可比性, 并可通

过患者在家中的日常活动来评估其症状。

PKG 的报告利用 PKG 数据记录仪来收集患者的活动数据。PKG 数据记录仪还可根据诊治医生的医嘱提醒患者何时服用他们的左旋多巴。

帕金森病患者所佩戴的 PKG 数据记录仪，经过十天时间收集到的数据经由 GKC 公司分析后转化成 PKG 报告，并自动送达给患者的诊治医师。

#### 类别

设备类: 神经科

#### 关键技术或领先技术的发展阶段

产品已经上市

#### 合作机会

共同合作研发  
寻求项目投资的机会

---

## Directory of Australian medtech companies



#### **COMPANY DETAILS**

**Company name:** Global Kinetics Corporation

**Key contact name:** Andrew Maxwell

**Job title of key contact:** Manager Director & CEO

**Company website address:** [www.globalkineticscorp.com](http://www.globalkineticscorp.com)

**Company address:** Level 6, 530 Collins Street, Melbourne VIC 3000

**The company is Unlisted.**

#### **ABOUT THE COMPANY**

Global Kinetics Corporation (GKC) is a medical technology company headquartered in Melbourne, Australia. Established in 2007, GKC's lead product is the Parkinson's KinetiGraph (PKG).

The PKG provides treating neurologists with a detailed report about the presence and severity of the key disabling movement disorders of Parkinson's disease – bradykinesia and dyskinesia. This report enables medical professionals to determine whether medication regimes are appropriate or need to be altered. Data contained within the PKG report is gathered by a watch-like data logger which is worn by the patient at home over ten days.

GKC is focused on globally commercialising the PKG enabling neurologists to better manage movement disorders, patients to enjoy a better quality of life and payors to achieve improved health economic outcomes. The PKG has TGA approval, and CE mark and is currently being used in hospitals for routine management of Parkinson's in Asia, Europe and Australia. FDA market clearance will be completed in 2014.

### **KEY OR LEAD TECHNOLOGY**

The PKG report provides clinician's with an assessment of a patient's clinical state which is objective, includes scaled measures of bradykinesia and dyskinesia, links symptom fluctuations with the timing of medication, is comparable over time and allows assessment of a patient's symptoms at home during the activities of daily living.

The PKG Report is produced using movement data collected by a PKG data logger. The PKG data logger also reminds patients when to take their levodopa medication as prescribed by their treating clinician.

People with Parkinson's disease wear the PKG data logger to record their movement over a period of ten days. The data collected is analysed by GKC, converted into a PKG report and delivered automatically to the patients treating clinician.

### **Category**

**Devices:** Neurology

### **Point of development of key or lead technology**

Product on the market

### **OPPORTUNITIES SOUGHT**

Research partnership  
Seeking investment.